MedTrace Logo

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

NCT01545570 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2017-07-25

No results posted yet for this study

Summary

This is a single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers. The study will enrol approximately 72 subjects at one clinical study center in the United States.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GSK2376497

GSK2376497 Active Comparator

DRUG

0.9% sodium chloride

0.9% sodium chloride Placebo Comparator

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-07
Primary Completion
2012-12-23
Completion
2012-12-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01545570 on ClinicalTrials.gov